IntraCellular Therapies (ITCI)
(Delayed Data from NSDQ)
$76.48 USD
+1.62 (2.16%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $76.46 -0.02 (-0.03%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Intra-Cellular Therapies (ITCI) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$93.40 | $120.00 | $65.00 | 24.77% |
Price Target
Based on short-term price targets offered by 15 analysts, the average price target for Intra-Cellular Therapies comes to $93.40. The forecasts range from a low of $65.00 to a high of $120.00. The average price target represents an increase of 24.77% from the last closing price of $74.86.
Analyst Price Targets (15)
Broker Rating
Intra-Cellular Therapies currently has an average brokerage recommendation (ABR) of 1.53 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 15 brokerage firms. The current ABR compares to an ABR of 1.40 a month ago based on 15 recommendations.
Of the 15 recommendations deriving the current ABR, 10 are Strong Buy and two are Buy. Strong Buy and Buy respectively account for 66.67% and 13.33% of all recommendations. A month ago, Strong Buy made up 73.33%, while Buy represented 13.33%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/ITCI.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 10 | 10 | 11 | 11 | 11 |
Buy | 2 | 2 | 2 | 2 | 2 |
Hold | 3 | 3 | 2 | 2 | 2 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.53 | 1.53 | 1.40 | 1.40 | 1.40 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
7/9/2024 | Not Identified | Not Identified | Moderate Buy | Moderate Buy |
6/25/2024 | UBS | Ashwani Verma | Strong Buy | Hold |
5/7/2024 | SVB Securities | Marc Goodman | Strong Buy | Strong Buy |
4/24/2024 | Cantor Fitzgerald & Co | Charles C Duncan | Strong Buy | Strong Buy |
4/23/2024 | Canaccord Genuity | Sumant Kulkarni | Strong Buy | Strong Buy |
4/22/2024 | Mizuho SecuritiesUSA | Graig Suvannavejh | Strong Buy | Strong Buy |
4/17/2024 | Robert W. Baird & Co. | Joel L Beatty | Strong Buy | Strong Buy |
4/17/2024 | Goldman Sachs | Corinne Johnson | Hold | Hold |
4/5/2024 | Needham & Company | Ami Fadia | Moderate Buy | Moderate Buy |
4/1/2024 | Cowen & Co. | Joseph Thome | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.53 |
ABR (Last week) | 1.53 |
# of Recs in ABR | 15 |
Average Target Price | $93.40 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 71 of 252 |
Current Quarter EPS Est: | -0.19 |